Instituto de Investigación e Innovación en Ciencias Biomédicas (INiBICA)
Institut de recherche
Hospital de Sagunto
Sagunto, EspañaPublications en collaboration avec des chercheurs de Hospital de Sagunto (11)
2024
-
Limitation of life support treatments in Spanish Intensive Care Units: Analysis of the ETHICUS II study
Medicina Intensiva, Vol. 48, Núm. 5, pp. 247-253
2022
-
ADENI-UCI Study: Analysis of non-income decisions in ICU as a measure of limitation of life support treatments
Medicina Intensiva, Vol. 46, Núm. 4, pp. 192-200
-
Recommendations for the management of critically ill patients with COVID-19 in Intensive Care Units
Medicina Intensiva, Vol. 46, Núm. 2, pp. 81-89
2021
-
The first wave of the COVID-19 epidemic in Spain was associated with early introductions and fast spread of a dominating genetic variant
Nature Genetics, Vol. 53, Núm. 10, pp. 1405-1414
2020
-
Update and recommendations in decision making referred to limitation of advanced life support treatment
Medicina Intensiva, Vol. 44, Núm. 2, pp. 101-112
2017
-
National survey on the indicators of quality in Bioethics of the SEMICYUC in the departments of Intensive Care Medicine in Spain
Medicina Intensiva, Vol. 41, Núm. 9, pp. 523-531
2016
-
Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome
Critical Care, Vol. 20, Núm. 1
-
Sarcoidosis: an update on current pharmacotherapy options and future directions
Expert Opinion on Pharmacotherapy, Vol. 17, Núm. 18, pp. 2431-2448
2014
2011
-
Impact of obesity in patients infected with 2009 influenza A(H1N1)
Chest, Vol. 139, Núm. 2, pp. 382-386
2004
-
Docetaxel plus epirubicin is a highly active, well-tolerated, first-line chemotherapy for metastatic breast cancer: Results of a large, multicentre phase II study
Cancer Chemotherapy and Pharmacology, Vol. 53, Núm. 1, pp. 75-81